—
C+
C+ The full Closelook — membership. Open the C+ overview

Cerus Corporation (CERS) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Cerus Corporation

CERS in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Cerus is a biomedical company that develops and sells the INTERCEPT Blood System, a technology that inactivates pathogens in donated blood before transfusion. Separate INTERCEPT lines treat platelets, plasma, red blood cells and cryoprecipitate, and an LED-based Illuminator device supports the treatment process. It sells through its own sales force and through distributors across the United States, Europe, the CIS, the Middle East and Latin America, and is based in Concord, California.
Where it sits in the stack
Cerus carries no seat in our index; it sits in the healthcare sector, within the medical-devices sleeve of our universe, alongside blood-safety and transfusion-technology names outside the AI build-out that our index otherwise tracks.
Who it is priced against
The diary has not assigned Cerus to a Closelook peer group; the market sometimes places it against Terumo Corporation, which also makes blood-processing and transfusion equipment.
Why Closelook tracks it
Cerus holds no index seat and carries no Closelook score, and the diary has recorded no quotes on it; coverage so far is limited to its chart readings.
What the diary watches
Whether adoption of pathogen-reduction systems widens across blood banks and transfusion services, which would shift the balance between its platelet, plasma and red-cell product lines.

Cerus Corporation (CERS) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for CERS, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Medical Devices · US · 8 names with week and year-to-date

Peer group

Medical Devices · US

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against CERS on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Cerus Corporation (CERS)?

Cerus Corporation trades as CERS on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-18.

Is CERS in a Closelook index?

Not currently — Cerus Corporation is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does CERS trade against its moving averages?

Pullback inside an uptrend stack: Trades -2.8% vs the 50-day and +10.7% vs the 200-day average, 23.3% below the 52-week high and +118% off the 52-week low. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Cerus Corporation do?

Cerus is a biomedical company that develops and sells the INTERCEPT Blood System, a technology that inactivates pathogens in donated blood before transfusion. Separate INTERCEPT lines treat platelets, plasma, red blood cells and cryoprecipitate, and an LED-based Illuminator device supports the treatment process. It sells through its own sales force and through distributors across the United States, Europe, the CIS, the Middle East and Latin America, and is based in Concord, California. The diary has not assigned Cerus to a Closelook peer group; the market sometimes places it against Terumo Corporation, which also makes blood-processing and transfusion equipment.

Where does Cerus Corporation sit in the AI build-out?

Cerus carries no seat in our index; it sits in the healthcare sector, within the medical-devices sleeve of our universe, alongside blood-safety and transfusion-technology names outside the AI build-out that our index otherwise tracks. Cerus holds no index seat and carries no Closelook score, and the diary has recorded no quotes on it; coverage so far is limited to its chart readings.

What does this page show?

A live price chart with SMA overlays and drawing tools for CERS, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Medical Devices. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.